KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBIT (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed EBIT for 16 consecutive years, with -$862000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 23.99% year-over-year to -$862000.0, compared with a TTM value of -$2.1 million through Sep 2025, up 68.2%, and an annual FY2024 reading of -$4.8 million, up 44.15% over the prior year.
  • EBIT was -$862000.0 for Q3 2025 at TherapeuticsMD, down from -$695000.0 in the prior quarter.
  • Across five years, EBIT topped out at $48.4 million in Q4 2022 and bottomed at -$39.9 million in Q3 2021.
  • Average EBIT over 5 years is -$5.0 million, with a median of -$1.8 million recorded in 2023.
  • The sharpest move saw EBIT surged 171.66% in 2021, then tumbled 103.33% in 2023.
  • Year by year, EBIT stood at $24.8 million in 2021, then skyrocketed by 95.32% to $48.4 million in 2022, then crashed by 103.33% to -$1.6 million in 2023, then soared by 118.93% to $305000.0 in 2024, then plummeted by 382.62% to -$862000.0 in 2025.
  • Business Quant data shows EBIT for TXMD at -$862000.0 in Q3 2025, -$695000.0 in Q2 2025, and -$871000.0 in Q1 2025.